Semler

Semler Scientific to Report Fourth Quarter and Year End 2023 Financial Results and Host Conference Call on March 5, 2024

Retrieved on: 
Wednesday, February 21, 2024
Semler, Internet, Conditional sentence, PIN

Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day.

Key Points: 
  • Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day.
  • Renae Cormier, chief financial officer, and Jennifer Oliva-Herrington, chief operating officer, will join him on the call.
  • We encourage participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10185342/fb4eeec618 .
  • Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator.

Semler Scientific Reports Third Quarter and Year-to-Date 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Investment, Growth, Semler, PIN, Conditional sentence, MD, Diagnosis, Internet, Cryptocurrency, Pharmaceutical industry, Music, Reinsurance, Chemical

SANTA CLARA, Calif., Nov. 9, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the three and nine months ended September 30, 2023.

Key Points: 
  • For the quarter ended September 30, 2023, compared to the corresponding period of 2022, Semler Scientific reported:
    Revenue of $16.3 million, an increase of $2.3 million, or 16%, compared to $14.0 million.
  • Fixed fee software license revenues of $9.5 million, an increase of $0.9 million, or 11%, compared to $8.6 million.
  • Semler Scientific's three largest customers (including their affiliates) comprised 36%, 28% and 11% of third quarter revenues in 2023.
  • The call will address results of the third quarter and nine months ended September 30, 2023, as well as provide a business update on Semler Scientific's strategies for the near-term future.

Semler Scientific to Report Third Quarter and First Nine Months of 2023 Financial Results and Host Conference Call on November 9, 2023

Retrieved on: 
Thursday, October 26, 2023
Semler, Conditional sentence, Internet, PIN, Pharmaceutical industry

Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day.

Key Points: 
  • Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day.
  • Renae Cormier, chief financial officer, and Jennifer Oliva-Herrington, chief operating officer, will join him on the call.
  • We encourage participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10182979/fa8e2b792d .
  • Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator.

Semler Scientific Reports Second Quarter and First Half of 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
Semler, Conditional sentence, PIN, MD, Investment, Internet, Cryptocurrency, Pharmaceutical industry, Chemical, Music, Video game, Renewable energy, Reinsurance

SANTA CLARA, Calif., Aug. 10, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the three and six months ended June 30, 2023.

Key Points: 
  • For the quarter ended June 30, 2023, compared to the corresponding period of 2022, Semler Scientific reported:
    Revenue of $18.6 million, an increase of $3.8 million, or 25%, compared to $14.8 million.
  • Fixed fee software license revenues were $9.6 million, an increase of $1.1 million, or 13%, compared to $8.5 million.
  • Semler Scientific's two largest customers (including their affiliates) comprised 37% and 34% of second quarter revenues in 2023.
  • The call will address results of the second quarter ended June 30, 2023, as well as provide a business update on Semler Scientific's strategies for the near-term future.

Semler to Report Second Quarter 2023 Financial Results and Host Conference Call on August 10, 2023

Retrieved on: 
Friday, July 28, 2023
Conditional sentence, PIN, Semler, Internet, Pharmaceutical industry

Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day.

Key Points: 
  • Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day.
  • Renae Cormier, chief financial officer, will join him on the call.
  • We encourage participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10179834/f9b1852ee8 .
  • Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator.

Semler Scientific Announces Appointment of Chief Financial Officer, Record Quarterly Revenues and Strategic Streamlining

Retrieved on: 
Tuesday, July 11, 2023
Semler, CFO, Conditional sentence, Growth, History, Moyamoya disease, Accounting, Pharmaceutical industry, Management

"We are pleased to announce Ms. Renae Cormier will lead our accounting, finance, investor relations and business strategy efforts as chief financial officer," said Doug Murphy-Chutorian, Semler Scientific's interim chief executive officer.

Key Points: 
  • "We are pleased to announce Ms. Renae Cormier will lead our accounting, finance, investor relations and business strategy efforts as chief financial officer," said Doug Murphy-Chutorian, Semler Scientific's interim chief executive officer.
  • "In addition, we expect to report record high revenues for the quarter ending June 30, 2023.
  • Furthermore, Semler Scientific will streamline its operations to provide enhanced efficiencies."
  • Semler Scientific also announced a strategic plan to streamline operations and reduce employee headcount by approximately 30% by September 15, 2023.

Semler Scientific Announces Appointment of Eric Semler and William Chang as Directors

Retrieved on: 
Wednesday, April 19, 2023
Businessperson, San Francisco, Bachelor, Software as a service, Dell, The New York Times, Harvard University, Semler, The Moscow News, Parent, PAD, Language, Dartmouth College, Strategic planning, San Francisco Port of Embarkation, Moyamoya disease, DHI (company), San Francisco Giants, Maven, NBA, B.A, Diagnosis, Book, Management, Security (finance), Economics

SANTA CLARA, Calif., April 19, 2023 /PRNewswire/ -- - Semler Scientific, Inc. (Nasdaq: SMLR) today announced that Eric Semler and William H.C. Chang (together, the "Investors"), who collectively beneficially own more than 20% of Semler Scientific's outstanding shares, will immediately join Semler Scientific's board of directors as new independent directors. Mr. Semler will join the board as a Class II director standing for reelection at the 2023 annual meeting of stockholders and will be appointed as Chairman of the board, and Mr. Chang will join the board as a Class I director standing for reelection at the 2025 annual meeting of stockholders. The board will temporarily expand to seven members before reverting to five members following the 2023 annual meeting as Ms. Moon and Dr. Leibowitz, current Class II directors have indicated their intent not to stand for re-election.

Key Points: 
  • SANTA CLARA, Calif., April 19, 2023 /PRNewswire/ -- - Semler Scientific, Inc. (Nasdaq: SMLR) today announced that Eric Semler and William H.C. Chang (together, the "Investors"), who collectively beneficially own more than 20% of Semler Scientific's outstanding shares, will immediately join Semler Scientific's board of directors as new independent directors.
  • Messrs. Semler and Chang collectively bring deep expertise in capital allocation, corporate governance, strategic planning, and investment management.
  • In connection with these appointments, Semler Scientific has entered into a mutual cooperation agreement with the Investors.
  • Mr. Semler said, "I am pleased to have reached an agreement with Semler Scientific and look forward to joining its board of directors as Chairman.

Semler Scientific Comments on CMS Risk Adjustment Changes in the 2024 Medicare Advantage and Part D Final Rate Announcement

Retrieved on: 
Monday, April 3, 2023
HD, Medicare Advantage, CMS, Risk adjusted mortality rate, Centers for Medicare & Medicaid Services, Semler, PAD, Risk, MACE, Medicare, Journal, Patient, Collection, Physician, Peripheral artery disease, Diagnosis, Mortality, American Heart, Pharmaceutical industry

SANTA CLARA, Calif., April 3, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, commented on the recent Centers for Medicare and Medicaid Services (CMS) 2024 Medicare Advantage and Part D Final Rate Announcement.

Key Points: 
  • SANTA CLARA, Calif., April 3, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, commented on the recent Centers for Medicare and Medicaid Services (CMS) 2024 Medicare Advantage and Part D Final Rate Announcement.
  • "Semler Scientific remains confident that screening for peripheral artery disease (PAD) using our QuantaFlo® product is in the best interest of at-risk Medicare beneficiaries, despite CMS' decision to finalize removal of PAD without complications from its Medicare Advantage risk adjustment model," said Wayne T. Pan, Ph.D., M.D., chief executive officer of Semler Scientific.
  • " The removal of PAD without complications from the Medicare Advantage risk adjustment model was originally proposed by CMS in its 2024 Medicare Advantage and Part D Advance Notice, which CMS released in February 2023.
  • Semler Scientific believes that the paradigm of earlier diagnosis and intervention will become the standard of care in managing patients with PAD and/or HD.

Semler Scientific Names Wayne T. Pan, M.D., Ph.D., M.B.A. as New CEO Effective April 3, 2023

Retrieved on: 
Tuesday, March 21, 2023
Banner Health, University, Semler, Wharton School of the University of Pennsylvania, Biotechnology, Health equity, University of Pennsylvania, Audit committee, Medicine, Johns Hopkins University, Growth, Diagnosis, Compensated emancipation, Management, Medical device, Biology

has informed the board of directors of his intention to step down from his position as chief executive officer (CEO) of Semler Scientific and assist for a transition period.

Key Points: 
  • has informed the board of directors of his intention to step down from his position as chief executive officer (CEO) of Semler Scientific and assist for a transition period.
  • Semler Scientific's board of directors is pleased to announce the appointment of Wayne T. Pan, M.D., Ph.D., M.B.A., age 59, as CEO to succeed Dr. Murphy-Chutorian.
  • Dr. Pan's appointment as CEO will be effective from April 3, 2023 and Dr. Pan will remain a member of our board of directors.
  • "I am very grateful for the opportunity to serve as CEO of Semler Scientific and lead the company into its next phase of growth.

Semler Reports Fourth Quarter and Year-to-Date 2021 Financial Results

Retrieved on: 
Monday, February 28, 2022
Risk, Income, Medicare, Conditional sentence, Population, PIN, Growth, Semler, Efficiency, Total, Type 1 diabetes, Internet, Tax, PAD, COVID-19, Vascular disease, Ageing, Adoption, Risk management, Disease, Alzheimer's disease, Nasdaq, Patient, Technology, Solution, Behavior, Mortality, Health, Insulin, Medical device, Pharmaceutical industry, Animal, Fossil fuel, Bookkeeping, Music, Life insurance, Security (finance), Video game

"In 2021 as compared to 2020, we experienced a timing shift in the home-testing market (fee-per-test), which led to first half revenue being greater than the second half of 2021."

Key Points: 
  • "In 2021 as compared to 2020, we experienced a timing shift in the home-testing market (fee-per-test), which led to first half revenue being greater than the second half of 2021."
  • In 2021, Semler Scientific's two largest customers comprised 40.8% and 28.6% of annual revenues and 48.6% and 21.7% of fourth quarter revenues.
  • By the end of the fourth quarter, Semler Scientific signed up several customers for this software product.
  • The call will address results of the fourth quarter and year ended December 31, 2021 as well as provide a business update on its market outlook and strategies for the near-term future.